Navigation Links
Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
Date:6/18/2012

LAUSANNE, Switzerland and SUZHOU, China, June 18, 2012 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a global biopharmaceutical development group that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc. (Ascepion), a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialisation of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development. ASP-08126 is a potent orally available small molecule that binds and inhibits several tyrosine kinase oncogenes implicated in many aspects of cancer development including tumour growth, metastasis, and tumour angiogenesis. ASP-08126 is expected to be effective in the treatment of various solid tumours as a mono-therapeutic agent or in combination with other anti-cancer therapies.

"The potential of Debio 1144 to simultaneously inhibit many aspects of cancer development is making that substance extremely attractive to Debiopharm", said Rolland-Yves Mauvernay, President and founder of Debiopharm, who added "Debio 1144 has the potential of helping patients suffering from several tumour types. Due to its inhibition profile Debio 1144, is expected to lead to high anti-tumour efficacy."

"We are very pleased to collaborate with Debiopharm, a company with track records and expertise in the development of cancer medicines, to develop our innovative cancer therapeutics. The formation of this partnership will facilitate the development of ASP-08126 and benefit cancer patients ultimately", stated Dr. Shan Jiang, President and CEO of Ascepion Pharmaceuticals.

About Debiopharm Group

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with
'/>"/>

SOURCE The Debiopharm Group and Ascepion Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
2. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
3. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
4. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
5. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
8. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
10. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
(Date:7/30/2015)... ... July 30, 2015 , ... In an effort to provide the twenty four ... a change in his practice. , The decision will also allow him to spend ... will be transferring his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... ... software, TikiLIVE, has worked to protect victims in San Diego, California’s Gaslamp Quarter ... used by Gaslamp Quarter Plaza actively monitor the area for any suspicious ...
(Date:7/30/2015)... ... ... " DevExpress ” was featured on NewsWatch as part ... large businesses making an impact in their industry. Susan Bridges, a reporter for ... how DevExpress has provided software development tools that have helped app developers build ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Beryl Institute announces ... In partnership with Patient Experience Institute, these offerings reinforce the commitment to help ... lines and throughout the experience movement, and provide information and research to support ...
(Date:7/30/2015)... Newport Beach, California (PRWEB) , ... July 30, ... ... products and services, announced today that the latest issue of Inclusive™ magazine, its ... multiple digital platforms. The digital edition of the new issue, Volume 6, Issue ...
Breaking Medicine News(10 mins):Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4
... North Carolina law firm sponsors bicycle safety video public service announcement ... ... February 17, 2009 -- HensonFuerst is giving local teens the chance ... announcement (PSA) contest in eastern North Carolina this spring. The mission ...
... CHICAGO, Feb. 17 While the common perception about ... is that it,s a rich person,s game, a Chicago ... eight years that we,ve been matching surrogates with our ... personal sacrifices. And nobody,s ever shown regret," says Robin ...
... Angeles Jewish Home are in it for the , Long ... Feb. 17 At the Los Angeles Jewish Home, one ... roof in the U.S. all agree on two things: They ... have the best ideas on just how to accomplish that ...
... Brighter smiles await,children in the Los Angeles area ... Oral Health Improvement Program to the La Canada,and Pacoima ... (Logo: http://www.newscom.com/cgi-bin/prnh/20011026/BIGLOTSLOGO ) , ... Smiles, Bright Futures dental van and its team,of dental ...
... that blocking the activity of a protein in the blood ... the study, normal mice and mice that had a genetically ... ultraviolet light that mimics chronic sun exposure. The mice that ... vascular skin cancer tumors than did the normal mice. , ...
... Michael Marmot, chair of the World Health Organization ... of the International Institute for Society and Health ... Positive Health Lecture Series talk, "Social Determinants of ... Health Lecture Series is organized by Martin Seligman, ...
Cached Medicine News:Health News:HensonFuerst Invites North Carolina Teens to Make Their Directorial Debuts 2Health News:The Surrogacy Journey: Not Just For the Wealthy 2Health News:Unique Group of 90-Year-Olds Share Top Ten Longevity Tips 2Health News:Unique Group of 90-Year-Olds Share Top Ten Longevity Tips 3Health News:Colgate's Bright Smiles, Bright Futures Program Brings Free Children's Dental Screenings to Los Angeles Area Big Lots Stores 2Health News:Blocking protein leads to fewer, smaller skin cancer tumors 2Health News:Blocking protein leads to fewer, smaller skin cancer tumors 3Health News:Blocking protein leads to fewer, smaller skin cancer tumors 4
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: